AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15899653 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamins C and E, beta-carotene, and selenium) along with methimazole therapy
Number of subjects: 55
Study 15899653 — intervention group
Group type: COMPARATOR
Intervention: Methimazole therapy alone
Number of subjects: 55
Study 15899653 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 55
Study 12237730 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic blood transfusion
Number of subjects: 0
Study 12237730 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestorage leukoreduction
Number of subjects: 0
Study 9523214 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAXA mutation screening
Number of subjects: 433
Study 9523214 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAXE mutation screening
Number of subjects: 433
Study 7640130 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium 0.5 mg kg‐1
Number of subjects: 80
Study 7640130 — intervention group
Group type: COMPARATOR
Intervention: vecuronium 0.1 mg kg‐1
Number of subjects: 80
Study 2677301 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen, 50 mg b.i.d.
Number of subjects: 56
Study 2677301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 318715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (dosages dependent on body weight)
Number of subjects: 44
Study 318715 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated co-twins)
Number of subjects: 44
Study 31756291 — intervention group
Group type: EXPERIMENTAL
Intervention: cSAM phenotype at index admission (kwashiorkor)
Number of subjects: 1704
Study 31756291 — intervention group
Group type: EXPERIMENTAL
Intervention: cSAM phenotype at index admission
Number of subjects: 1704
Study 31567791 — intervention group
Group type: EXPERIMENTAL
Intervention: Front Squat (FS)
Number of subjects: 24
Study 31567791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumo Deadlift (SD)
Number of subjects: 24
Study 27022012 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis + Stent Group
Number of subjects: 0
Study 27022012 — intervention group
Group type: COMPARATOR
Intervention: Catheter-directed thrombolysis Alone Group
Number of subjects: 0
Study 26159179 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate access to a fully automated online assessment and intervention with personalized feedback
Number of subjects: 1605
Study 26159179 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to a fully automated online assessment and intervention with personalized feedback
Number of subjects: 1605
Study 23727740 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000ppm sodium fluoride
Number of subjects: 30
Study 23727740 — intervention group
Group type: EXPERIMENTAL
Intervention: GC MI paste plus
Number of subjects: 30
Study 23727740 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro tooth crème
Number of subjects: 30
Study 20737210 — intervention group
Group type: COMPARATOR
Intervention: Oral 5-aminosalicylic acid (5-ASA) alone
Number of subjects: 26
Study 20737210 — intervention group
Group type: COMPARATOR
Intervention: Oral 5-ASA plus oral Lactobacillus casei DG
Number of subjects: 26
Study 20737210 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-ASA and rectal Lactobacillus casei DG
Number of subjects: 26
Study 19283953 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-positive individuals
Number of subjects: 0
Study 19283953 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-positive men
Number of subjects: 0
Study 19283953 — intervention group
Group type: EXPERIMENTAL
Intervention: Criminal risk factors
Number of subjects: 0
Study 16634751 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg day(-1) for 1 week
Number of subjects: 96
Study 16634751 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg on day 1, then 75 mg day(-1)) for 1 week
Number of subjects: 96
Study 16634751 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 96
Study 16634751 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and Clopidogrel
Number of subjects: 96
Study 14523094 — intervention group
Group type: EXPERIMENTAL
Intervention: Input from temporal retina in albinism
Number of subjects: 0
Study 14523094 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal routing of temporal fibers
Number of subjects: 0
Study 14523094 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal input to visual cortex in human albinism
Number of subjects: 0
Study 14523094 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal input in striate and extrastriate areas
Number of subjects: 0
Study 14523094 — intervention group
Group type: EXPERIMENTAL
Intervention: Topographic mapping in human albinism
Number of subjects: 0
Study 11009291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy
Number of subjects: 62
Study 11009291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 8629306 — intervention group
Group type: COMPARATOR
Intervention: Triple drug therapy with a 10-day course of OKT3 (group 2, n = 44)
Number of subjects: 129
Study 8629306 — intervention group
Group type: COMPARATOR
Intervention: Triple drug therapy with anti-interleukin-2 receptor monoclonal antibody LO-Tact-1 (group 3, n = 43)
Number of subjects: 129
Study 8629306 — intervention group
Group type: COMPARATOR
Intervention: Triple drug therapy (cyclosporine, steroids, and azathioprine; group 1, n = 42)
Number of subjects: 129
Study 8629306 — intervention group
Group type: COMPARATOR
Intervention: OKT3 therapy (group 2)
Number of subjects: 129
Study 8629306 — intervention group
Group type: COMPARATOR
Intervention: LO-Tact-1 therapy (group 3)
Number of subjects: 129
Study 1424170 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel LAR 25 mg
Number of subjects: 21
Study 1424170 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel LAR 50 mg
Number of subjects: 21
Study 1424170 — intervention group
Group type: EXPERIMENTAL
Intervention: Parlodel LAR 100 mg
Number of subjects: 21
Study 2413294 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (2 mg . kg‐1)
Number of subjects: 14
Study 2413294 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside alone (Control)
Number of subjects: 14
Study 31895254 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable suture lifting
Number of subjects: 12
Study 29307093 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping TNF inhibitors (TNFi) therapy
Number of subjects: 35
Study 29307093 — intervention group
Group type: COMPARATOR
Intervention: Continuing TNF inhibitors (TNFi) therapy
Number of subjects: 35
Study 26796966 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 31
Study 26796966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 27129011 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 75 mg every 12 hours and Diltiazem 240 mg/day
Number of subjects: 0
Study 27129011 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg every 12 hours and Hydrochlorothiazide 25 mg/day
Number of subjects: 0
Study 27129011 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg every 12 hours and Propranolol 40-80 mg every 12 hours
Number of subjects: 0
Study 21969362 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) prevention system
Number of subjects: 4407
Study 20334647 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin Treatment Questionnaire (IITQ)
Number of subjects: 1076
Study 19281060 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive sensory stimulation through tactile coactivation applied to the fingertips for 3 hours.
Number of subjects: 0
Study 15449184 — intervention group
Group type: EXPERIMENTAL
Intervention: 188Re-HEDP (3194+/‐387 MBq)
Number of subjects: 46
Study 15449184 — intervention group
Group type: EXPERIMENTAL
Intervention: 153Sm-EDTMP (2940+/‐545 MBq)
Number of subjects: 46
Study 15201490 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient EQ
Number of subjects: 1
Study 15201490 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 1
Study 11523081 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for analysis of repeated binary outcomes
Number of subjects: 0
Study 11523081 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for stratified analysis
Number of subjects: 0
Study 11523081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern mixture model
Number of subjects: 0
Study 11523081 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of proposed method
Number of subjects: 0
Study 11523081 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal risk ratio estimation
Number of subjects: 0
Study 9263086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of cefamandole at induction of anesthesia (group 1, n = 24)
Number of subjects: 69
Study 9263086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of cefamandole at the beginning of anesthesia followed by an additional dose (2 g) immediately after onset of cardiopulmonary bypass (CPB) (group 2, n = 22)
Number of subjects: 69
Study 9263086 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g of cefamandole just at the initiation of anesthesia (group 3, n = 23)
Number of subjects: 69
Study 9263086 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 69
Study 7508065 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg daily
Number of subjects: 12
Study 7508065 — intervention group
Group type: COMPARATOR
Intervention: Captopril 12.5 mg three times daily
Number of subjects: 12
Study 3533236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.5 mg (approximately 0.007 mg X kg‐1)
Number of subjects: 60
Study 3533236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 1.0 mg (approximately 0.015 mg X kg‐1)
Number of subjects: 60
Study 3533236 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine 0.05 mg X kg‐1
Number of subjects: 60
Study 3533236 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine 0.1 mg X kg‐1
Number of subjects: 60
Study 3533236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 29575929 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape
Number of subjects: 74
Study 29575929 — intervention group
Group type: COMPARATOR
Intervention: Matopat Classic adhesive tape (placebo)
Number of subjects: 74
Study 26763075 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguinarine (SA) at 10 mg kg(‐1) BW
Number of subjects: 0
Study 26763075 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguinarine (SA) at 0, 5, 10 and 20 mg kg(‐1) BW
Number of subjects: 0
Study 25515398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (50 g)
Number of subjects: 14
Study 25515398 — intervention group
Group type: COMPARATOR
Intervention: Glucose (50 g)
Number of subjects: 14
Study 25515398 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (50 g)
Number of subjects: 14
Study 22139591 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG XR 300 mg/day
Number of subjects: 226
Study 22139591 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG XR 250 mg/day
Number of subjects: 226
Study 22139591 — intervention group
Group type: COMPARATOR
Intervention: Historical control (aggregated pseudoplacebo data from 8 trials)
Number of subjects: 226
Study 20459697 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 21
Study 20459697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 18639417 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 165
Study 18639417 — intervention group
Group type: COMPARATOR
Intervention: Coumarin
Number of subjects: 165
Study 16146552 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 5-10 mg/d for 4 years
Number of subjects: 14
Study 12966256 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic Pain Questionnaire (NPQ)
Number of subjects: 528
Study 10815342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory rehabilitation programme (intensive care and post-assistance programme)
Number of subjects: 0
Study 10815342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory rehabilitation programme (intensive care only)
Number of subjects: 0
Study 10815342 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-assistance programme (nine-months with 36 sessions of psychoanalytic group therapy)
Number of subjects: 0
Study 10815342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis
Number of subjects: 0
Study 10815342 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilisation of the health care system
Number of subjects: 0
Study 8829887 — intervention group
Group type: EXPERIMENTAL
Intervention: Core cooling via intravenous infusion of cold saline
Number of subjects: 0
Study 8829887 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-surface cooling
Number of subjects: 0
Study 8829887 — intervention group
Group type: EXPERIMENTAL
Intervention: Shivering
Number of subjects: 0
Study 8829887 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal stimuli resulting in core hypothermia
Number of subjects: 0
Study 8829887 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-surface cooling without core hypothermia
Number of subjects: 0
Study 1622904 — intervention group
Group type: EXPERIMENTAL
Intervention: Silc-cup
Number of subjects: 199
Study 1622904 — intervention group
Group type: COMPARATOR
Intervention: Metal cup
Number of subjects: 199
Study 6531663 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (propranolol, 100 mg orally)
Number of subjects: 6
Study 6531663 — intervention group
Group type: COMPARATOR
Intervention: No beta-blockade (control)
Number of subjects: 6
Study 30914073 — intervention group
Group type: EXPERIMENTAL
Intervention: BD+50 mg EEO/kg
Number of subjects: 800
Study 30914073 — intervention group
Group type: EXPERIMENTAL
Intervention: BD+100 mg EEO/kg
Number of subjects: 800
Study 30914073 — intervention group
Group type: EXPERIMENTAL
Intervention: BD+150 mg OEO/kg
Number of subjects: 800
Study 30914073 — intervention group
Group type: EXPERIMENTAL
Intervention: BD+300 mg OEO/kg
Number of subjects: 800
Study 30914073 — intervention group
Group type: COMPARATOR
Intervention: BD (control)
Number of subjects: 800
Study 29044707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU, two doses at baseline and 8 weeks)
Number of subjects: 120
Study 29044707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo at baseline and 8 weeks)
Number of subjects: 120
Study 26998954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 5 mg intravenously
Number of subjects: 16
Study 26998954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg intravenously
Number of subjects: 16
Study 26998954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg intravenously
Number of subjects: 16
Study 26998954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg orally
Number of subjects: 16
Study 24667664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nursing care with electronic followup system
Number of subjects: 840
Study 21940922 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-taught PE (90 minutes per week from visiting specialists)
Number of subjects: 620
Study 21940922 — intervention group
Group type: COMPARATOR
Intervention: Common-practice PE (150 minutes per week from generalist classroom teachers)
Number of subjects: 620
Study 21395144 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective endotoxin hemoperfusion with Polymyxin B and Alteco LPS adsorber
Number of subjects: 0
Study 21395144 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17272337 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks (50, 100, 150, up to 175 J)
Number of subjects: 154
Study 17272337 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shocks (100, 200, 300, up to 360 J)
Number of subjects: 154
Study 17272337 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 154
Study 17272337 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shocks
Number of subjects: 154
Study 17272337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 16234460 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D animations and surgical videos (n=90)
Number of subjects: 172
Study 16234460 — intervention group
Group type: COMPARATOR
Intervention: Surgical videos only (n=82)
Number of subjects: 172
Study 11820865 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ 10 mg
Number of subjects: 2
Study 11820865 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ 20 mg
Number of subjects: 2
Study 11820865 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ 40 mg
Number of subjects: 2
Study 11820865 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ 80 mg
Number of subjects: 2
Study 11820865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 10424325 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone alone (1000 mg)
Number of subjects: 18
Study 10424325 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone with proguanil (1000 mg + 400 mg)
Number of subjects: 18
Study 10424325 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil alone (400 mg)
Number of subjects: 18
Study 10424325 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil with atovaquone (400 mg + 1000 mg)
Number of subjects: 18
Study 7802104 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amisulpride
Number of subjects: 20
Study 7802104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2104072 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam intravenously rapidly over 2‐4 s (Group A)
Number of subjects: 100
Study 2104072 — intervention group
Group type: COMPARATOR
Intervention: Diazepam intravenously over 1‐2 min, mean dose 15.9 mg (Group B)
Number of subjects: 100
Study 477025 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 29
Study 477025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 31934844 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation (MMR) programme
Number of subjects: 603
Study 31934844 — intervention group
Group type: COMPARATOR
Intervention: Ordinary care and treatment in primary care (reference group)
Number of subjects: 603
Study 30803472 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 120
Study 30803472 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 120
Study 28244124 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopy and possible treatment escalation
Number of subjects: 44
Study 28244124 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 44
Study 25548839 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeomin (XEO)
Number of subjects: 80
Study 25548839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (DYS)
Number of subjects: 80
Study 25548839 — intervention group
Group type: COMPARATOR
Intervention: Both Xeomin and Dysport
Number of subjects: 80
Study 24201169 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal continuous oxygen therapy (TCOT) for 4 weeks as an adjunct to standard care.
Number of subjects: 17
Study 24201169 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control group).
Number of subjects: 17
Study 24201169 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal continuous oxygen therapy (TCOT).
Number of subjects: 17
Study 21867492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational reminder (FOBT plus a mailed reminder)
Number of subjects: 769
Study 21867492 — intervention group
Group type: COMPARATOR
Intervention: Usual care (FOBT alone)
Number of subjects: 769
Study 21867492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed educational reminder
Number of subjects: 769
Study 19286091 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 530348 10 mg
Number of subjects: 1030
Study 19286091 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 530348 20 mg
Number of subjects: 1030
Study 19286091 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 530348 40 mg
Number of subjects: 1030
Study 19286091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study 19286091 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 530348 0.5 mg
Number of subjects: 1030
Study 19286091 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 530348 1.0 mg
Number of subjects: 1030
Study 19286091 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 530348 2.5 mg
Number of subjects: 1030
Study 17398194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/40 mg/day
Number of subjects: 1873
Study 17398194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study 15033841 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet + educational pack
Number of subjects: 1213
Study 15033841 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet + multifaceted intervention
Number of subjects: 1213
Study 18007128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 0
Study 18007128 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 18007128 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment tools for classification
Number of subjects: 0
Study 10823375 — intervention group
Group type: EXPERIMENTAL
Intervention: Microparticle enzyme immunoassay (MEIA)
Number of subjects: 74
Study 10823375 — intervention group
Group type: COMPARATOR
Intervention: High-performance liquid chromatography-mass spectrometry (HPLC-MS)
Number of subjects: 74
Study 10823375 — intervention group
Group type: EXPERIMENTAL
Intervention: Time after transplantation
Number of subjects: 74
Study 10823375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin concentration
Number of subjects: 74
Study 8722747 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of breast cancer in first-degree relatives
Number of subjects: 41837